Observational studyClinical rheumatology2025
A retrospective study of electrocardiographic alterations in primary Sjögren's syndrome: role of anti-SSA positivity and disease duration.
Observational study in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating anti-Ro/Sjögren's syndrome-related antigen A antibodies and risk of heart rate-corrected QT interval prolongation: a meta-analysis.European heart journal open · 2026Article
- Sjogren's Disease-Aspects of Clinical Disease Beyond Dry Eyes/Mouth.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary Sjögren's Syndrome (pSS) is a chronic autoimmune disorder affecting exocrine glands and potentially leading to cardiovascular complications. The impact of anti-SSA antibody seropositivity on cardiac function, particularly ECG parameters, is not well understood.
aimsThis study aims to explore the association between anti-SSA antibody seropositivity and various ECG parameters, including the QT interval, corrected QT interval (QTc), QT dispersion, and T peak to T end (TP-TE) interval, in patients with pSS.
methodsA retrospective observational study was conducted involving 57 pSS patients. Participants were divided into seropositive (n = 32) and seronegative (n = 25) groups based on anti-SSA antibody status. ECG parameters were assessed, including QT interval, QTc interval, QT dispersion, and TP-TE interval. Statistical comparisons were made using independent t-tests, Mann-Whitney U tests, or chi-square tests, with a significance threshold of p < 0.05.
resultsThe seropositive group showed significantly prolonged QT interval (403.1 ± 28.7 ms) compared to the seronegative group (381.8 ± 28.2 ms, p < 0.01). Similarly, the QTc interval was longer in seropositive patients (430.1 ± 28.6 ms) compared to seronegative patients (412.6 ± 31.8 ms, p = 0.03). QT dispersion was greater in the seropositive group (43.5 ± 3.6 ms) compared to the seronegative group (40.8 ± 4.6 ms, p = 0.02). The TP-TE interval was also significantly prolonged in seropositive patients (67.9 ± 7.5 ms) compared to seronegative patients (63.4 ± 4.8 ms, p < 0.01). The TP-TE/QTc ratio did not differ significantly between the two groups.
conclusionsAnti-SSA seropositivity in pSS patients is associated with significant alterations in ECG parameters indicative of impaired ventricular repolarization. These findings suggest that seropositive pSS patients may have an increased risk of cardiovascular complications, emphasizing the importance of ECG monitoring in this patient population. Key Points •Anti-Ro/SSA seropositivity in pSS patients is linked to prolonged QT and QTc intervals, indicating impaired ventricular repolarization. •Seropositive pSS patients show increased QT dispersion, which may reflect a higher risk for arrhythmias. •The TP-TE interval is significantly prolonged in seropositive pSS patients, suggesting a higher risk for ventricular arrhythmias. •ECG monitoring is crucial in seropositive pSS patients to detect early cardiac abnormalities and guide treatment.
Indexed as
Identifiers
40346441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.